• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Case Reports in Gastroenterology >A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy Ascites and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir
【2h】

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy Ascites and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir

机译：通过Sofosbuvir / Velpatasvir抗病毒治疗患有肝癌腹水和胸腔积液消失的丙型肝炎病毒相关的失代偿肝硬化患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Moreover, many DAAs include an indication for compensated liver cirrhosis. However, patients with decompensated HCV-associated cirrhosis have hitherto not been indicated for therapy with DAAs. Recently, a new DAA, sofosbuvir/velpatasvir (SOF/VEL), was indicated for decompensated HCV-associated cirrhotic patients. Actually, it has been shown to eradicate HCV in many cases. However, it is not clear whether hepatic encephalopathy, ascites, and pleural effusion in patients with decompensated HCV-associated cirrhosis disappear by SOF/VEL treatment. Recently, we encountered a decompensated HCV-associated cirrhosis patient who showed the disappearance of hepatic encephalopathy, ascites, and pleural effusion with marked improvement of serum ammonia level, albumin level, prothrombin time, and platelet count after the eradication of HCV by the administration of SOF/VEL. Her consciousness was cloudy and it took many hours for the preparation of each meal just before SOF/VEL treatment, but after the disappearance of HCV-RNA by the therapy, her consciousness became clear and she could prepare meals in a short time. This case suggests the possibility of improvement from decompensated HCV-associated liver cirrhosis to compensated liver cirrhosis with disappearance of hepatic encephalopathy, ascites, and pleural effusion by SOF/VEL therapy.
机译：口服直效抗病毒（DAAs）是日本丙型肝炎病毒（HCV）病毒（HCV）的主要疗法。此外，许多DAA包括补偿肝硬化的指示。然而，迄今为止没有表明迄今为止具有失代偿的HCV相关的肝硬化患者。最近，为失代偿的HCV相关的肝硬化患者表示新的DAA，Sofosbuvir / VelpataSvir（SOF / VEL）。实际上，已经显示出在许多情况下消除HCV。然而，目前尚不清楚肝脏脑病，腹水和胸腔积液是否通过SOF / VEL治疗消失的肝硬化患者。最近，我们遇到了一种失代偿的HCV相关的肝硬化患者，该患者患有肝脏脑病，腹水和胸腔积液的消失，并在通过给药后发现HCV后显着改善了血清氨水位，白蛋白水平，凝血酶原时间和血小板计数SOF / VEL。她的意识是多云，在SOF / VEL治疗之前，每餐都花了很多时间，但在治疗后HCV-RNA消失后，她的意识变得清晰，她可以在短时间内准备饭菜。这种情况表明，通过SOF / VEL疗法消失，通过消失的肝脑病，腹水和胸腔积液的消失，从失代偿的HCV相关肝硬化改善的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号